Sonas Pharma, a biotechnology startup developing therapeutics for obesity and epilepsy, has secured pre-seed funding led by SFC Capital, with participation from Clarendon Fund Managers. The investment will support development of endocannabinoid system-based therapeutics and expansion of research capabilities.
It is building mechanism-driven therapeutics based on GPCR pharmacology, peripheral restriction and rational drug design. Its work includes a CB1-targeting metabolic programme using neutral, peripherally restricted pharmacology, alongside an epilepsy drug discovery platform focused on neurological disease.
Funding will accelerate advancement of its metabolic programme, continued development of its epilepsy platform, expansion of core research and development capabilities and early-stage translational infrastructure, and recruitment of scientific and operational staff.
We’re thrilled to have the backing of SFC Capital and Clarendon Fund Managers as we build a new generation of endocannabinoid system therapeutics. Their support validates our mechanismfirst strategy and allows us to advance programs designed to deliver real clinical impact in two areas of huge unmet medical need in epilepsy and obesity.
Sonas Pharma stands out with its rigorous scientific foundation and clear strategy for addressing major unmet needs in metabolic and neurological disease. We’re excited to support their growth at this early stage.
We are delighted to invest in Sonas through the Invest NI-backed Co-Fund and to support the company as it progresses towards important development milestones. Sonas has the foundations to build a best-in-class drug discovery company from Northern Ireland. This investment reflects our continued commitment to supporting ambitious local businesses with global reach.
